×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Infertility Market Share

ID: MRFR/LS/4687-HCR
100 Pages
Rahul Gotadki
February 2026

Infertility Market Research Report By Treatment Type (Assisted Reproductive Technology, Hormone Therapy, Surgery, Fertility Preservation), By End User (Hospitals, Fertility Clinics, Home Care Settings), By Gender (Female, Male), By Cause of Infertility (Ovulatory Disorders, Uterine or Cervical Abnormalities, Tubal Factors, Male Factor Infertility) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Infertility Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Market Share

Infertility Market Share Analysis

The Infertility Market is witnessing dynamic strategies for market share positioning as it addresses a crucial element of reproductive health. With an emphasis on offering solutions to couples having trouble conceiving, businesses in this industry deliberately navigate the competitive landscape to increase their market position. Businesses are aggressively entering new international markets. This entails setting up fertility facilities, forming alliances with medical professionals, and guaranteeing that infertility treatments are accessible in various areas. The different needs of couples looking for reproductive treatments around the world are met by global expansion. Businesses are concentrating on tailored medicine since they understand how different every infertility issue is. More efficient and patient-centered reproductive treatments are made possible by customized treatment programs based on genetic variables, lifestyle factors, and unique patient profiles. Innovation is essential, especially when it comes to preserving fertility. Businesses are spending money on research to advance sperm and egg-freezing technology, giving people the choice to freeze their fertility for future family planning. Businesses are funding patient and healthcare professional education programs. Raising knowledge about the reasons for infertility, accessible therapies, and the emotional aspects of fertility journeys is facilitated by educational campaigns, counseling services, and training programs. Embracing the digital transformation, companies are integrating fertility services with telehealth options. Remote consultations, virtual monitoring, and telemedicine platforms increase accessibility and convenience in fertility care, especially for patients in remote areas. Companies are incorporating sustainability features into their infertility treatment programs. This includes eco-friendly clinic practices, responsible waste management, and efforts to reduce the environmental impact of fertility treatment procedures. Companies that recognize the impact of male factors in infertility are creating solutions that center on the reproductive health of men. This covers developments in male fertility therapies, sperm analysis, and the treatment of disorders that impact male fertility. Innovations in reproductive health are the subject of ongoing research. Businesses are spending money on research to investigate cutting-edge technology like artificial intelligence for predicting fertility, improvements in embryo selection, and creative methods to increase the success rates of infertility treatments. Businesses are looking into integrating their services with genetic counseling. Giving couples undergoing assisted reproductive procedures thorough genetic information on potential dangers and conditions related to fertility treatments helps them make educated decisions.

Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Infertility Market as of 2024?

<p>The Infertility Market was valued at approximately 2035.28 USD Million in 2024.</p>

What is the projected market valuation for the Infertility Market in 2035?

<p>The market is projected to reach a valuation of around 7671.5 USD Million by 2035.</p>

What is the expected CAGR for the Infertility Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Infertility Market during the forecast period 2025 - 2035 is 12.82%.</p>

Which treatment type segment is expected to have the highest valuation in 2035?

<p>The In Vitro Fertilization segment is anticipated to reach approximately 3000.0 USD Million by 2035.</p>

How does the market for Female Factor Infertility compare to Male Factor Infertility in 2035?

<p>By 2035, the Female Factor Infertility segment is projected to be valued at around 3200.0 USD Million, significantly higher than the Male Factor Infertility segment at approximately 1200.0 USD Million.</p>

What are the projected valuations for Assisted Reproductive Technology segments in 2035?

<p>In 2035, the Egg Donation segment is expected to reach about 3871.5 USD Million, while Cryopreservation is projected at 1200.0 USD Million.</p>

Which age group is expected to contribute the most to the Infertility Market by 2035?

<p>The age group of 25 to 34 is projected to contribute significantly, with a valuation of approximately 3030.75 USD Million by 2035.</p>

What role do fertility clinics play in the Infertility Market?

<p>Fertility clinics are expected to be a major contributor, with a projected valuation of around 3000.0 USD Million by 2035.</p>

How is the market for telemedicine expected to evolve by 2035?

<p>The telemedicine segment is projected to grow, reaching an estimated valuation of 971.5 USD Million by 2035.</p>

Who are the key players in the Infertility Market?

<p>Key players in the Infertility Market include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and others.</p>

Market Summary

As per MRFR analysis, the Infertility Market Size was estimated at 2035.28 USD Million in 2024. The Infertility industry is projected to grow from 2296.2 in 2025 to 7671.5 by 2035, exhibiting a compound annual growth rate (CAGR) of 12.82% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The infertility market is experiencing dynamic growth driven by technological advancements and changing societal norms.

  • Technological advancements in treatment are revolutionizing the infertility market, particularly in North America.
  • Increased awareness and education regarding reproductive health are fostering a more informed patient base in the Asia-Pacific region.
  • The shift in societal norms is leading to changing family planning trends, impacting both female and male factor infertility segments.
  • Rising infertility rates and advancements in reproductive technologies are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 2035.28 (USD Million)
2035 Market Size 7671.5 (USD Million)
CAGR (2025 - 2035) 12.82%
Largest Regional Market Share in 2024 North America

Major Players

CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Irvine Scientific (US), Vitrolife (SE), Reproductive Health Specialists (US), OvaScience (US), Genea (AU), IVF Technologies (US)

Market Trends

The Infertility Market is currently experiencing a notable evolution, driven by a confluence of factors that include advancements in medical technology, increasing awareness of reproductive health, and shifting societal norms regarding family planning. As individuals and couples seek solutions to infertility challenges, the demand for innovative treatments and services is on the rise. This market encompasses a wide array of offerings, from assisted reproductive technologies to fertility preservation methods, reflecting a growing recognition of the complexities surrounding conception. Furthermore, the integration of telemedicine and digital health solutions is reshaping how patients access care, making it more convenient and accessible than ever before. In addition to technological advancements, the Infertility Market is influenced by changing demographics and lifestyle choices. Factors such as delayed parenthood, increased prevalence of reproductive disorders, and the rising incidence of lifestyle-related infertility are contributing to a heightened focus on fertility solutions. As a result, stakeholders within this market, including healthcare providers, pharmaceutical companies, and research institutions, are actively exploring new avenues for growth and innovation. The future landscape of the Infertility Market appears promising, with ongoing research and development efforts likely to yield novel therapies and improved patient outcomes.

Technological Advancements in Treatment

The Infertility Market is witnessing a surge in technological innovations that enhance treatment efficacy. Techniques such as in vitro fertilization and genetic screening are becoming more refined, leading to higher success rates. Additionally, the emergence of artificial intelligence in diagnostics and personalized treatment plans is revolutionizing patient care.

Increased Awareness and Education

There is a growing emphasis on education regarding reproductive health, which is fostering a more informed public. Campaigns aimed at destigmatizing infertility are encouraging individuals to seek help sooner. This trend is likely to drive demand for fertility services and support networks.

Shift in Societal Norms

Societal attitudes towards family planning are evolving, with more individuals choosing to delay parenthood for various reasons. This shift is contributing to an increase in infertility cases, thereby expanding the market for fertility treatments. As societal acceptance grows, so does the willingness to explore assisted reproductive options.

Infertility Market Market Drivers

Market Growth Projections

The Global Infertility Market Industry is projected to experience substantial growth in the coming years. By 2024, the market is anticipated to reach 19.7 USD Billion, with further expansion expected to 30.5 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate (CAGR) of 4.03% from 2025 to 2035. Such projections highlight the increasing demand for infertility treatments and services, driven by factors such as rising infertility rates, technological advancements, and greater awareness. As the market evolves, stakeholders are likely to explore new opportunities for innovation and investment, positioning themselves to meet the needs of a growing patient population.

Rising Prevalence of Infertility

The Global Infertility Market Industry is witnessing a notable increase in infertility rates, attributed to various factors such as delayed childbearing and lifestyle changes. According to recent data, approximately 15% of couples globally experience infertility issues. This rising prevalence is driving demand for fertility treatments and services, contributing to the market's projected growth. By 2024, the market is expected to reach 19.7 USD Billion, reflecting a growing awareness and acceptance of assisted reproductive technologies. As more individuals seek solutions for infertility, the industry is likely to expand, fostering innovation in treatment options and enhancing patient access.

Government Initiatives and Support

Government policies and initiatives play a crucial role in shaping the Global Infertility Market Industry. Many countries are implementing programs to support infertility treatments, including funding for research and subsidies for patients. For example, some nations offer financial assistance for IVF procedures, making them more accessible to a broader population. These initiatives not only alleviate the financial burden on couples but also encourage the development of advanced fertility clinics and services. As governments recognize the importance of addressing infertility, the market is likely to benefit from increased investment and support, further driving growth in the coming years.

Demographic Shifts and Lifestyle Changes

Demographic changes, including an aging population and evolving lifestyle choices, are significantly impacting the Global Infertility Market Industry. As individuals prioritize education and career advancement, many are delaying family planning, which can lead to increased infertility rates. Additionally, lifestyle factors such as obesity, smoking, and stress are contributing to fertility challenges. These shifts necessitate a greater demand for fertility solutions, as couples seek to overcome the biological limitations associated with age and lifestyle. The market's growth is expected to reflect these demographic trends, with a notable increase in service utilization as awareness of fertility issues rises.

Technological Advancements in Fertility Treatments

Innovations in reproductive technologies are significantly influencing the Global Infertility Market Industry. Techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT) are becoming increasingly sophisticated. These advancements not only improve success rates but also enhance patient experiences. For instance, the introduction of artificial intelligence in embryo selection has shown promising results in optimizing outcomes. As these technologies evolve, they are expected to attract more patients, thereby propelling the market forward. The anticipated growth trajectory suggests that by 2035, the market could reach 30.5 USD Billion, underscoring the importance of continuous innovation.

Increasing Awareness and Acceptance of Fertility Treatments

The Global Infertility Market Industry is experiencing a shift in societal attitudes towards fertility treatments. Increased awareness campaigns and educational initiatives are helping to destigmatize infertility and promote available treatment options. As a result, more individuals and couples are seeking assistance, leading to a rise in demand for fertility services. This trend is particularly evident in urban areas where access to information is more prevalent. The growing acceptance of assisted reproductive technologies is expected to contribute to a compound annual growth rate (CAGR) of 4.03% from 2025 to 2035, indicating a robust market expansion driven by informed consumer choices.

Market Segment Insights

By Treatment Type: In Vitro Fertilization (Largest) vs. Intracytoplasmic Sperm Injection (Fastest-Growing)

In the infertility market's treatment type segment, In Vitro Fertilization (IVF) holds the largest share, reflecting its established effectiveness and widespread acceptance among patients. On the other hand, Intracytoplasmic Sperm Injection (ICSI) is the fastest-growing treatment option, gaining traction due to advancements in male infertility solutions and its ability to improve fertilization rates with severe sperm issues. Ovulation Induction and Artificial Insemination follow but are comparatively smaller in terms of market penetration. Furthermore, the growth trends in this segment are influenced by various factors, including an increasing prevalence of infertility, rising awareness about reproductive health, and technological advancements in fertility treatments. The growing acceptance of ART (Assisted Reproductive Technology) contributes significantly to the expansion of treatments like ICSI. Moreover, changes in lifestyle and environmental factors are also driving the demand for effective infertility solutions in today's society.

IVF (Dominant) vs. ICSI (Emerging)

In Vitro Fertilization (IVF) is a dominant treatment in the infertility market due to its long-standing application and proven success rates, making it a go-to option for couples facing fertility issues. The treatment involves the careful retrieval of eggs and sperm, followed by the creation of embryos in a laboratory setting, which are then implanted in the uterus, giving hopeful parents a significant chance of conception. Meanwhile, Intracytoplasmic Sperm Injection (ICSI) serves as an emerging treatment, particularly beneficial for male infertility cases. This technique involves injecting a single sperm directly into an egg, making it a vital choice for couples who struggle with sperm viability or motility. As ICSI continues to innovate and expand its applications, it is quickly becoming a critical component in the comprehensive approach to infertility treatments.

By Cause of Infertility: Female Factor Infertility (Largest) vs. Male Factor Infertility (Fastest-Growing)

The infertility market exhibits a diverse distribution of causes, with female factor infertility holding the largest share. This segment encompasses a variety of issues, including ovulatory disorders, age-related decline in fertility, and structural problems within the reproductive system. On the other hand, male factor infertility, which includes problems such as low sperm count and motility, is rapidly rising as a significant concern, reflecting changing lifestyle factors and increased awareness surrounding male reproductive health.

Female Factor Infertility (Dominant) vs. Male Factor Infertility (Emerging)

Female factor infertility is characterized by its multifaceted nature, encompassing hormonal imbalances, age-related fertility decline, and anatomical issues. This segment remains dominant in the infertility market due to heightened public awareness and a growing number of women seeking fertility treatments. Conversely, male factor infertility is emerging as a critical concern, driven by lifestyle choices such as obesity, smoking, and environmental exposures. As societal norms evolve, more men are undergoing fertility assessments, leading to greater demand for treatments and contributing to its rapidly growing status in the overall infertility landscape.

By Age Group: 25 to 34 (Largest) vs. 35 to 44 (Fastest-Growing)

The age group of 25 to 34 holds the largest share in the infertility market, as this demographic is typically when individuals and couples are more actively seeking fertility treatments. The prevalence of infertility issues, combined with increased awareness and access to treatments, has led to a significant concentration of market demand among this age group. In contrast, the 35 to 44 age group is witnessing rapid growth, as more individuals are delaying parenthood for various reasons and subsequently facing fertility challenges, making this segment increasingly prominent in the market.

25 to 34 (Dominant) vs. 35 to 44 (Emerging)

The 25 to 34 age group is characterized by a proactive approach towards family planning, leading to its dominance in the infertility market. Often, individuals in this bracket are more open to seeking help and exploring options such as IVF or fertility preservation. Meanwhile, the 35 to 44 age group is emerging rapidly due to demographic shifts and late marriages, which have increased their vulnerability to infertility. This segment often includes women facing age-related fertility decline, compelling a significant portion to seek treatments, thus boosting overall market growth and the demand for innovative reproductive technologies.

By Assisted Reproductive Technology: Cryopreservation (Largest) vs. Preimplantation Genetic Testing (Fastest-Growing)

<p>The Assisted Reproductive Technology segment within the infertility market showcases a diverse range of options, with Cryopreservation being the largest contributor. This method holds significant market share due to its extensive use in various fertility treatments, allowing for the preservation of eggs, sperm, and embryos, which is crucial for individuals and couples seeking assisted reproductive options. In contrast, Preimplantation Genetic Testing, while currently smaller in market share, is gaining traction due to rising consumer awareness and advancements in genetic screening technologies, providing critical insights into embryo viability, thereby enhancing the success rates of IVF procedures. The growth trends in this segment highlight a strong shift towards innovative and personalized reproductive solutions. The increasing incidence of infertility issues, coupled with advancements in medical technology and increasing investments in fertility clinics, are propelling the demand for both Cryopreservation and Preimplantation Genetic Testing. The latter's rapid adoption reflects a growing desire for genetic reassurance among prospective parents, indicating a promising outlook for continued expansion in the future.</p>

<p>Cryopreservation (Dominant) vs. Sperm Donation (Emerging)</p>

<p>Cryopreservation stands out as the dominant method within the Assisted Reproductive Technology segment due to its ability to preserve reproductive cells and embryos for future use, making it a cornerstone of fertility preservation strategies. This technique is especially beneficial for individuals facing medical treatments that may impair reproductive capabilities or for those who wish to delay parenthood. Conversely, Sperm Donation is emerging as a crucial alternative for many individuals and couples dealing with male infertility issues or those opting for single-parenthood. The increasing acceptance of sperm donation as a viable reproductive choice marks a significant societal shift and highlights a broader trend towards utilizing diverse reproductive technologies to accommodate varying reproductive needs.</p>

By Healthcare Setting: Fertility Clinics (Largest) vs. Telemedicine (Fastest-Growing)

<p>The infertility market within healthcare settings is primarily dominated by fertility clinics, which cater specifically to individuals seeking assisted reproductive technologies. These clinics hold a significant share due to their specialized services, personalized patient care, and advanced treatment options. In contrast, hospitals also play a critical role, providing a wide range of healthcare services that include infertility treatments, yet they often lack the dedicated focus of specialized clinics. Home care solutions and telemedicine are emerging segments, gaining traction as they offer convenience and innovative alternatives to traditional treatment methods.</p>

<p>Fertility Clinics (Dominant) vs. Telemedicine (Emerging)</p>

<p>Fertility clinics stand as the dominant force in the infertility market, offering tailored services that meet the unique needs of patients seeking fertility assistance. These clinics are equipped with cutting-edge technology and a team of specialists committed to helping individuals achieve pregnancy through various methods, such as in vitro fertilization (IVF) and intrauterine insemination (IUI). On the other hand, telemedicine is emerging rapidly as a supplementary option, providing patients access to fertility consultations and treatment plans from the comfort of their homes. This growth is driven by technological advancements and increasing patient demand for flexible healthcare solutions, allowing for a more comprehensive approach to treatment.</p>

Get more detailed insights about Infertility Market Research Report – Forecast to 2035

Regional Insights

North America : Leading Market for Infertility Solutions

North America is poised to maintain its leadership in the infertility market, holding a significant share of 1010.0 million in 2025. Key growth drivers include increasing awareness of infertility issues, advancements in reproductive technologies, and supportive government policies. The rising prevalence of infertility, coupled with a growing demand for assisted reproductive technologies (ART), is expected to further boost market growth in this region. Regulatory frameworks are also evolving to support innovative treatments and ensure patient safety. The competitive landscape in North America is robust, featuring key players such as CooperSurgical, Merck KGaA, and Irvine Scientific. The U.S. is the leading country, accounting for the majority of the market share, driven by high healthcare expenditure and advanced medical infrastructure. The presence of numerous fertility clinics and research institutions enhances the region's capability to innovate and provide cutting-edge solutions. This competitive environment fosters collaboration and investment in new technologies, ensuring continued growth in the infertility sector.

Europe : Emerging Hub for Fertility Innovations

Europe's infertility market is projected to reach 680.0 million by 2025, driven by increasing infertility rates and a growing acceptance of ART. Factors such as favorable regulations, enhanced healthcare access, and rising public awareness are pivotal in shaping market dynamics. The European Union's initiatives to standardize ART practices and improve patient access to treatments are expected to further stimulate market growth. Additionally, the integration of advanced technologies in fertility treatments is enhancing success rates, attracting more patients. Leading countries in this region include Germany, France, and the UK, which are home to several prominent fertility clinics and research institutions. Key players like Merck KGaA and Ferring Pharmaceuticals are actively involved in developing innovative solutions. The competitive landscape is characterized by collaborations between healthcare providers and technology firms, aiming to enhance treatment efficacy and patient outcomes. This synergy is crucial for maintaining Europe's position as a leader in the infertility market.

Asia-Pacific : Rapidly Growing Fertility Market

The Asia-Pacific infertility market is expected to grow significantly, reaching 300.0 million by 2025. This growth is driven by increasing awareness of infertility issues, rising disposable incomes, and advancements in reproductive technologies. Countries like China and India are witnessing a surge in demand for ART, fueled by changing societal norms and a growing middle class. Additionally, supportive government policies and investments in healthcare infrastructure are enhancing access to fertility treatments across the region. China and India are the leading countries in this market, with a growing number of fertility clinics and healthcare providers. The competitive landscape is evolving, with both local and international players, such as Genea and Vitrolife, expanding their presence. The increasing collaboration between healthcare providers and technology firms is fostering innovation in treatment options, ensuring that the Asia-Pacific region remains a key player in The Infertility.

Middle East and Africa : Emerging Market with Growth Potential

The Middle East and Africa infertility market is projected to reach 45.28 million by 2025, driven by increasing awareness of infertility and the growing acceptance of ART. Factors such as rising healthcare expenditure and improvements in medical infrastructure are contributing to market growth. Additionally, cultural shifts towards seeking medical assistance for infertility are encouraging more individuals to pursue treatment options. Regulatory bodies are also beginning to establish guidelines to ensure the safety and efficacy of fertility treatments. Countries like South Africa and the UAE are leading the market, with a growing number of fertility clinics and healthcare providers. The competitive landscape is characterized by both local and international players, with a focus on providing affordable and accessible infertility solutions. Key players are investing in technology and partnerships to enhance treatment options, positioning the region for future growth in the infertility market.

Key Players and Competitive Insights

The Infertility Market is characterized by a dynamic competitive landscape, driven by increasing awareness of reproductive health and advancements in assisted reproductive technologies (ART). Key players such as CooperSurgical (US), Merck KGaA (DE), and Ferring Pharmaceuticals (CH) are strategically positioned to leverage innovation and expand their market presence. CooperSurgical (US) focuses on enhancing its product portfolio through acquisitions and partnerships, while Merck KGaA (DE) emphasizes research and development to introduce cutting-edge solutions. Ferring Pharmaceuticals (CH) is actively pursuing global expansion, particularly in emerging markets, thereby shaping the competitive environment through diverse operational strategies.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which enhances operational efficiency. The collective influence of these major companies fosters a competitive atmosphere where innovation and strategic partnerships are paramount for success.

In November CooperSurgical (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel fertility treatment. This collaboration is expected to enhance CooperSurgical's product offerings and strengthen its position in the market. The strategic importance of this partnership lies in its potential to accelerate the development of innovative therapies, thereby addressing the growing demand for effective infertility solutions.

In October Merck KGaA (DE) launched a new digital platform aimed at improving patient engagement and education regarding fertility treatments. This initiative reflects the company's commitment to digital transformation and positions it as a leader in providing comprehensive support to patients. The strategic significance of this move is underscored by the increasing reliance on digital tools in healthcare, which may enhance patient outcomes and satisfaction.

In September Ferring Pharmaceuticals (CH) expanded its manufacturing capabilities in Asia to meet the rising demand for its fertility medications. This expansion not only demonstrates Ferring's commitment to regional growth but also highlights the importance of supply chain optimization in maintaining product availability. The strategic relevance of this development is evident in its potential to enhance Ferring's competitive edge in a rapidly evolving market.

As of December current trends in the Infertility Market indicate a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of agility in responding to market demands.

Key Companies in the Infertility Market include

Industry Developments

The Global Infertility Market has seen notable developments recently, driven by advancements in reproductive technologies and increased awareness surrounding infertility issues. Companies such as Ferring Pharmaceuticals, Boston IVF, and Merck KGaA have been actively involved in launching innovative fertility treatments. 

For instance, in July 2023, Ferring Pharmaceuticals introduced a new product aimed at enhancing fertility efficiency, which is anticipated to improve patient outcomes. Significant mergers and acquisitions also characterize the market; Cook Medical acquired MediCorp in August 2023, aiming to expand its portfolio in reproductive health technologies, with major implications for collaboration and innovation in the sector. Furthermore, the valuation of companies like IVF Technologies and Vitrolife has surged due to rising demand for assisted reproductive technologies, reflecting a broader trend of increasing allocations towards Research and Development in this area. 

Over the last couple of years, a substantial shift towards telemedicine in fertility consultations has transformed patient access and care, indicating evolving consumer preferences in the Global Infertility Market landscape. As awareness grows and technology advances, the market is poised for sustained growth in the upcoming years.

Future Outlook

Infertility Market Future Outlook

The Infertility Market is projected to grow at a 12.82% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising infertility rates.

New opportunities lie in:

  • Expansion of telehealth services for remote consultations
  • Development of personalized fertility treatment plans
  • Investment in AI-driven diagnostic tools for infertility assessment

By 2035, the Infertility Market is expected to be robust, reflecting substantial growth and innovation.

Market Segmentation

Infertility Market Age Group Outlook

  • Under 25
  • 25 to 34
  • 35 to 44
  • 45 and Above

Infertility Market Technology Outlook

  • Assisted Reproductive Technology
  • Surgical Procedures
  • Pharmaceuticals
  • Genetic Testing

Infertility Market Treatment Type Outlook

  • In Vitro Fertilization
  • Intracytoplasmic Sperm Injection
  • Ovulation Induction
  • Artificial Insemination

Infertility Market Cause of Infertility Outlook

  • Male Factor Infertility
  • Female Factor Infertility
  • Unexplained Infertility
  • Combined Infertility

Infertility Market Patient Demographics Outlook

  • Single Women
  • Couples
  • Same-Sex Couples
  • Older Adults

Report Scope

MARKET SIZE 2024 2035.28(USD Million)
MARKET SIZE 2025 2296.2(USD Million)
MARKET SIZE 2035 7671.5(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 12.82% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Irvine Scientific (US), Vitrolife (SE), Reproductive Health Specialists (US), OvaScience (US), Genea (AU), IVF Technologies (US)
Segments Covered Treatment Type, Cause of Infertility, Age Group, Technology, Patient Demographics
Key Market Opportunities Advancements in personalized reproductive technologies enhance success rates in the Infertility Market.
Key Market Dynamics Rising demand for assisted reproductive technologies drives innovation and competition among infertility treatment providers.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Infertility Market as of 2024?

<p>The Infertility Market was valued at approximately 2035.28 USD Million in 2024.</p>

What is the projected market valuation for the Infertility Market in 2035?

<p>The market is projected to reach a valuation of around 7671.5 USD Million by 2035.</p>

What is the expected CAGR for the Infertility Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Infertility Market during the forecast period 2025 - 2035 is 12.82%.</p>

Which treatment type segment is expected to have the highest valuation in 2035?

<p>The In Vitro Fertilization segment is anticipated to reach approximately 3000.0 USD Million by 2035.</p>

How does the market for Female Factor Infertility compare to Male Factor Infertility in 2035?

<p>By 2035, the Female Factor Infertility segment is projected to be valued at around 3200.0 USD Million, significantly higher than the Male Factor Infertility segment at approximately 1200.0 USD Million.</p>

What are the projected valuations for Assisted Reproductive Technology segments in 2035?

<p>In 2035, the Egg Donation segment is expected to reach about 3871.5 USD Million, while Cryopreservation is projected at 1200.0 USD Million.</p>

Which age group is expected to contribute the most to the Infertility Market by 2035?

<p>The age group of 25 to 34 is projected to contribute significantly, with a valuation of approximately 3030.75 USD Million by 2035.</p>

What role do fertility clinics play in the Infertility Market?

<p>Fertility clinics are expected to be a major contributor, with a projected valuation of around 3000.0 USD Million by 2035.</p>

How is the market for telemedicine expected to evolve by 2035?

<p>The telemedicine segment is projected to grow, reaching an estimated valuation of 971.5 USD Million by 2035.</p>

Who are the key players in the Infertility Market?

<p>Key players in the Infertility Market include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and others.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Treatment Type (USD Million)
    2. | | 4.1.1 In Vitro Fertilization
    3. | | 4.1.2 Intracytoplasmic Sperm Injection
    4. | | 4.1.3 Artificial Insemination
    5. | | 4.1.4 Ovulation Induction
    6. | 4.2 Healthcare, BY Cause of Infertility (USD Million)
    7. | | 4.2.1 Male Factor Infertility
    8. | | 4.2.2 Female Factor Infertility
    9. | | 4.2.3 Unexplained Infertility
    10. | | 4.2.4 Combined Infertility
    11. | 4.3 Healthcare, BY Age Group (USD Million)
    12. | | 4.3.1 Under 25
    13. | | 4.3.2 25 to 34
    14. | | 4.3.3 35 to 44
    15. | | 4.3.4 45 and Above
    16. | 4.4 Healthcare, BY Assisted Reproductive Technology (USD Million)
    17. | | 4.4.1 Cryopreservation
    18. | | 4.4.2 Preimplantation Genetic Testing
    19. | | 4.4.3 Sperm Donation
    20. | | 4.4.4 Egg Donation
    21. | 4.5 Healthcare, BY Healthcare Setting (USD Million)
    22. | | 4.5.1 Fertility Clinics
    23. | | 4.5.2 Hospitals
    24. | | 4.5.3 Home Care
    25. | | 4.5.4 Telemedicine
    26. | 4.6 Healthcare, BY Region (USD Million)
    27. | | 4.6.1 North America
    28. | | | 4.6.1.1 US
    29. | | | 4.6.1.2 Canada
    30. | | 4.6.2 Europe
    31. | | | 4.6.2.1 Germany
    32. | | | 4.6.2.2 UK
    33. | | | 4.6.2.3 France
    34. | | | 4.6.2.4 Russia
    35. | | | 4.6.2.5 Italy
    36. | | | 4.6.2.6 Spain
    37. | | | 4.6.2.7 Rest of Europe
    38. | | 4.6.3 APAC
    39. | | | 4.6.3.1 China
    40. | | | 4.6.3.2 India
    41. | | | 4.6.3.3 Japan
    42. | | | 4.6.3.4 South Korea
    43. | | | 4.6.3.5 Malaysia
    44. | | | 4.6.3.6 Thailand
    45. | | | 4.6.3.7 Indonesia
    46. | | | 4.6.3.8 Rest of APAC
    47. | | 4.6.4 South America
    48. | | | 4.6.4.1 Brazil
    49. | | | 4.6.4.2 Mexico
    50. | | | 4.6.4.3 Argentina
    51. | | | 4.6.4.4 Rest of South America
    52. | | 4.6.5 MEA
    53. | | | 4.6.5.1 GCC Countries
    54. | | | 4.6.5.2 South Africa
    55. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 CooperSurgical (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Merck KGaA (DE)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Ferring Pharmaceuticals (CH)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Irvine Scientific (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Vitrolife (SE)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Reproductive Health Technologies (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 OvaScience (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Genea Limited (AU)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 HRC Fertility (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. | 6.4 US MARKET ANALYSIS BY CAUSE OF INFERTILITY
    5. | 6.5 US MARKET ANALYSIS BY AGE GROUP
    6. | 6.6 US MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    7. | 6.7 US MARKET ANALYSIS BY HEALTHCARE SETTING
    8. | 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    10. | 6.10 CANADA MARKET ANALYSIS BY AGE GROUP
    11. | 6.11 CANADA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    12. | 6.12 CANADA MARKET ANALYSIS BY HEALTHCARE SETTING
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    15. | 6.15 GERMANY MARKET ANALYSIS BY CAUSE OF INFERTILITY
    16. | 6.16 GERMANY MARKET ANALYSIS BY AGE GROUP
    17. | 6.17 GERMANY MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    18. | 6.18 GERMANY MARKET ANALYSIS BY HEALTHCARE SETTING
    19. | 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
    20. | 6.20 UK MARKET ANALYSIS BY CAUSE OF INFERTILITY
    21. | 6.21 UK MARKET ANALYSIS BY AGE GROUP
    22. | 6.22 UK MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    23. | 6.23 UK MARKET ANALYSIS BY HEALTHCARE SETTING
    24. | 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    25. | 6.25 FRANCE MARKET ANALYSIS BY CAUSE OF INFERTILITY
    26. | 6.26 FRANCE MARKET ANALYSIS BY AGE GROUP
    27. | 6.27 FRANCE MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    28. | 6.28 FRANCE MARKET ANALYSIS BY HEALTHCARE SETTING
    29. | 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    30. | 6.30 RUSSIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    31. | 6.31 RUSSIA MARKET ANALYSIS BY AGE GROUP
    32. | 6.32 RUSSIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    33. | 6.33 RUSSIA MARKET ANALYSIS BY HEALTHCARE SETTING
    34. | 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    35. | 6.35 ITALY MARKET ANALYSIS BY CAUSE OF INFERTILITY
    36. | 6.36 ITALY MARKET ANALYSIS BY AGE GROUP
    37. | 6.37 ITALY MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    38. | 6.38 ITALY MARKET ANALYSIS BY HEALTHCARE SETTING
    39. | 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    40. | 6.40 SPAIN MARKET ANALYSIS BY CAUSE OF INFERTILITY
    41. | 6.41 SPAIN MARKET ANALYSIS BY AGE GROUP
    42. | 6.42 SPAIN MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    43. | 6.43 SPAIN MARKET ANALYSIS BY HEALTHCARE SETTING
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY CAUSE OF INFERTILITY
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY HEALTHCARE SETTING
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    51. | 6.51 CHINA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    52. | 6.52 CHINA MARKET ANALYSIS BY AGE GROUP
    53. | 6.53 CHINA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    54. | 6.54 CHINA MARKET ANALYSIS BY HEALTHCARE SETTING
    55. | 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    56. | 6.56 INDIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    57. | 6.57 INDIA MARKET ANALYSIS BY AGE GROUP
    58. | 6.58 INDIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    59. | 6.59 INDIA MARKET ANALYSIS BY HEALTHCARE SETTING
    60. | 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    61. | 6.61 JAPAN MARKET ANALYSIS BY CAUSE OF INFERTILITY
    62. | 6.62 JAPAN MARKET ANALYSIS BY AGE GROUP
    63. | 6.63 JAPAN MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    64. | 6.64 JAPAN MARKET ANALYSIS BY HEALTHCARE SETTING
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY HEALTHCARE SETTING
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY AGE GROUP
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY HEALTHCARE SETTING
    75. | 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    76. | 6.76 THAILAND MARKET ANALYSIS BY CAUSE OF INFERTILITY
    77. | 6.77 THAILAND MARKET ANALYSIS BY AGE GROUP
    78. | 6.78 THAILAND MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    79. | 6.79 THAILAND MARKET ANALYSIS BY HEALTHCARE SETTING
    80. | 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    81. | 6.81 INDONESIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    82. | 6.82 INDONESIA MARKET ANALYSIS BY AGE GROUP
    83. | 6.83 INDONESIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    84. | 6.84 INDONESIA MARKET ANALYSIS BY HEALTHCARE SETTING
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY CAUSE OF INFERTILITY
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY AGE GROUP
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY HEALTHCARE SETTING
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    92. | 6.92 BRAZIL MARKET ANALYSIS BY CAUSE OF INFERTILITY
    93. | 6.93 BRAZIL MARKET ANALYSIS BY AGE GROUP
    94. | 6.94 BRAZIL MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    95. | 6.95 BRAZIL MARKET ANALYSIS BY HEALTHCARE SETTING
    96. | 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    97. | 6.97 MEXICO MARKET ANALYSIS BY CAUSE OF INFERTILITY
    98. | 6.98 MEXICO MARKET ANALYSIS BY AGE GROUP
    99. | 6.99 MEXICO MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    100. | 6.100 MEXICO MARKET ANALYSIS BY HEALTHCARE SETTING
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY AGE GROUP
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY HEALTHCARE SETTING
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY HEALTHCARE SETTING
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY CAUSE OF INFERTILITY
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY HEALTHCARE SETTING
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY HEALTHCARE SETTING
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY CAUSE OF INFERTILITY
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY AGE GROUP
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY HEALTHCARE SETTING
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    135. | 6.135 HEALTHCARE, BY CAUSE OF INFERTILITY, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY CAUSE OF INFERTILITY, 2024 TO 2035 (USD Million)
    137. | 6.137 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    139. | 6.139 HEALTHCARE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2024 TO 2035 (USD Million)
    141. | 6.141 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    5. | | 7.2.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    6. | | 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
    7. | | 7.2.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    8. | | 7.2.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    11. | | 7.3.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    12. | | 7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
    13. | | 7.3.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    14. | | 7.3.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    17. | | 7.4.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    18. | | 7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
    19. | | 7.4.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    20. | | 7.4.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    23. | | 7.5.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    24. | | 7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
    25. | | 7.5.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    26. | | 7.5.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    29. | | 7.6.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    30. | | 7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
    31. | | 7.6.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    32. | | 7.6.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    35. | | 7.7.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    36. | | 7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
    37. | | 7.7.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    38. | | 7.7.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    41. | | 7.8.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    42. | | 7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
    43. | | 7.8.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    44. | | 7.8.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    47. | | 7.9.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    48. | | 7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
    49. | | 7.9.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    50. | | 7.9.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    53. | | 7.10.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    54. | | 7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
    55. | | 7.10.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    56. | | 7.10.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    59. | | 7.11.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    60. | | 7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
    61. | | 7.11.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    62. | | 7.11.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    65. | | 7.12.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    66. | | 7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
    67. | | 7.12.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    68. | | 7.12.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    71. | | 7.13.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    72. | | 7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
    73. | | 7.13.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    74. | | 7.13.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    77. | | 7.14.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    78. | | 7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
    79. | | 7.14.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    80. | | 7.14.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    83. | | 7.15.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    84. | | 7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
    85. | | 7.15.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    86. | | 7.15.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    89. | | 7.16.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    90. | | 7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
    91. | | 7.16.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    92. | | 7.16.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    95. | | 7.17.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    96. | | 7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
    97. | | 7.17.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    98. | | 7.17.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    101. | | 7.18.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    102. | | 7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
    103. | | 7.18.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    104. | | 7.18.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    107. | | 7.19.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    108. | | 7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
    109. | | 7.19.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    110. | | 7.19.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    113. | | 7.20.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    114. | | 7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
    115. | | 7.20.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    116. | | 7.20.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    119. | | 7.21.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    120. | | 7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
    121. | | 7.21.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    122. | | 7.21.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    125. | | 7.22.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    126. | | 7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
    127. | | 7.22.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    128. | | 7.22.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    131. | | 7.23.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    132. | | 7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
    133. | | 7.23.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    134. | | 7.23.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    137. | | 7.24.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    138. | | 7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
    139. | | 7.24.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    140. | | 7.24.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    143. | | 7.25.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    144. | | 7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
    145. | | 7.25.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    146. | | 7.25.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    149. | | 7.26.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    150. | | 7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
    151. | | 7.26.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    152. | | 7.26.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    155. | | 7.27.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    156. | | 7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
    157. | | 7.27.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    158. | | 7.27.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    161. | | 7.28.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    162. | | 7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
    163. | | 7.28.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    164. | | 7.28.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    167. | | 7.29.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    168. | | 7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
    169. | | 7.29.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    170. | | 7.29.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
    173. | | 7.30.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    174. | | 7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
    175. | | 7.30.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
    176. | | 7.30.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Million, 2025-2035)

  • In Vitro Fertilization
  • Intracytoplasmic Sperm Injection
  • Artificial Insemination
  • Ovulation Induction

Healthcare By Cause of Infertility (USD Million, 2025-2035)

  • Male Factor Infertility
  • Female Factor Infertility
  • Unexplained Infertility
  • Combined Infertility

Healthcare By Age Group (USD Million, 2025-2035)

  • Under 25
  • 25 to 34
  • 35 to 44
  • 45 and Above

Healthcare By Assisted Reproductive Technology (USD Million, 2025-2035)

  • Cryopreservation
  • Preimplantation Genetic Testing
  • Sperm Donation
  • Egg Donation

Healthcare By Healthcare Setting (USD Million, 2025-2035)

  • Fertility Clinics
  • Hospitals
  • Home Care
  • Telemedicine
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓